

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	10217319
<b>Application Number:</b>	10788426
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	4965
<b>Title of Invention:</b>	NOVEL BICYCLIC UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS
<b>First Named Inventor/Applicant Name:</b>	Jacques Dumas
<b>Customer Number:</b>	23599
<b>Filer:</b>	Richard J. Traverso/Ashley Weber
<b>Filer Authorized By:</b>	Richard J. Traverso
<b>Attorney Docket Number:</b>	BAYER-0044
<b>Receipt Date:</b>	02-JUN-2011
<b>Filing Date:</b>	01-MAR-2004
<b>Time Stamp:</b>	16:53:39
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Foreign Reference	N20-JP01-200254Apatentandabstract.pdf	1368216 64b9f55c0b531e16d0906f02d43a1254809a8db	no	32

### Warnings:

### Information:

2	Foreign Reference	N21- JP01-259360patentandabstract.pdf	972277 5e45921676dd9462e7a2b441157a079b15 6e938	no	21
<b>Warnings:</b>					
<b>Information:</b>					
3	Foreign Reference	N22- JP02-022650patentandabstract.pdf	586045 44b6bed1363ebc6f4f64bcbff169f86ed49 a16b	no	12
<b>Warnings:</b>					
<b>Information:</b>					
4	Foreign Reference	N23- JP02-023337patentandabstract.pdf	2453615 8011e5c004e7eca7464812855186cc092b4e9f 90d6d9	no	43
<b>Warnings:</b>					
<b>Information:</b>					
5	Foreign Reference	N24- JP02-035450patentandabstract.pdf	933198 69c55c6d4906c398c30b6d6d7773b423 4ee56	no	19
<b>Warnings:</b>					
<b>Information:</b>					
6	Foreign Reference	N25- JP2-105146patentandabstract.pdf	1007468 77bf0f81aefb323c3644c8328b5d607972ac7 4663c	no	19
<b>Warnings:</b>					
<b>Information:</b>					
7	Foreign Reference	N26- JP21-08048Apatentandabstract.pdf	1047095 21286d613b70a2e451003d544506c3c30 04e76	no	21
<b>Warnings:</b>					
<b>Information:</b>					
8	Foreign Reference	N27- JP21-50840Apatentandabstract.pdf	1852752 30472031806c1206f0f9f964f88dc7eb0ff1f 3c	no	35
<b>Warnings:</b>					
<b>Information:</b>					
9	Foreign Reference	N28-JP353247A.pdf	2256105 012dcd53d3ef76465276c5c2035c396dab7c e4f82	no	53
<b>Warnings:</b>					
<b>Information:</b>					
10	Foreign Reference	N29- JP3-144634patentandabstract.pdf	1215788 d11ae3b6ac710c30b45f29170630224cdy b3ac4	no	27
<b>Warnings:</b>					
<b>Information:</b>					

11	Foreign Reference	N30- JP3-198049patentandabstract. pdf	1523798 <small>62c7fbce23480b6d8f781e13e3d7cc0d5de3ab</small>	no	32
<b>Warnings:</b>					
<b>Information:</b>					
12	Foreign Reference	N31-JP6-75172B2.pdf	2947143 <small>8b1d3b8c1c1f1392533d3365d29c5f8950633a</small>	no	83
<b>Warnings:</b>					
<b>Information:</b>					
13	Foreign Reference	N32-JP08-031841A.pdf	418830 <small>9017b3e9568fc7688b8462781721d398e229f3</small>	no	6
<b>Warnings:</b>					
<b>Information:</b>					
14	Foreign Reference	N33-JP10-306078a.pdf	1848801 <small>edc240d08c98bcbcb13ca8937b9bc2ee67667bd0</small>	no	102
<b>Warnings:</b>					
<b>Information:</b>					
15	Foreign Reference	O1-LB-6124.pdf	5408189 <small>55fa363a8f537168c1bae9f1ee02c32a383c93e</small>	no	120
<b>Warnings:</b>					
<b>Information:</b>					
16	Non Patent Literature	P7-Avuruch.pdf	815295 <small>51bf248becb69a2c86d4d980579dc37eeec2784</small>	no	5
<b>Warnings:</b>					
<b>Information:</b>					
17	Non Patent Literature	P9a- BakaetalAreviewoflatestclinical. pdf	881500 <small>202bd76cc3e89822ad8fa30596ae06ee0cd4</small>	no	10
<b>Warnings:</b>					
<b>Information:</b>					
18	Non Patent Literature	P10-BALANTLPETAL- METABOLICCONSIDERATIONS. PDF	2630313 <small>b0bdcdb1bc945d20318e466a3328f7e666ba0f4</small>	no	35
<b>Warnings:</b>					
<b>Information:</b>					
19	Non Patent Literature	P17- BERGESTEPHENMPLYEDBIGHLE YANDDONALDCMONKHOUSEP HARMACEUTICALSALTS.pdf	2779981 <small>2688aa03c1a2288c57915f41aeb0f1ba2604ad</small>	no	19
<b>Warnings:</b>					
<b>Information:</b>					

20	Non Patent Literature	P22-Martin-Blanco-p38MAPK.pdf	212665 9da6918b6ea715813bb6ccac569b332b5c73781	no	9
<b>Warnings:</b>					
<b>Information:</b>					
21	Non Patent Literature	P23-Foussard-Blanpin-ComparativePharmacodynamic study.pdf	324049 7673a9217ac16d80c26aef4f5c3bba415d94388	no	12
<b>Warnings:</b>					
<b>Information:</b>					
22	Non Patent Literature	P25-BOLLAGE TAL-RAFP pathway inhibitors.pdf	570524 124ef80134aca1caf11e164de30a1913a0b7239e8	no	6
<b>Warnings:</b>					
<b>Information:</b>					
23	Non Patent Literature	P26-Bolton et al Oncogene Directed Approaches in Cancer Chemotherapy.pdf	1322358 3d861bca2a7bf235ca2a3b266a05b585b7514221	no	10
<b>Warnings:</b>					
<b>Information:</b>					
24	Non Patent Literature	P28a-Boyer Small Molecule Inhibitors of IKK.pdf	2453975 41b6072d857d4f1b4b5ea358fe63d5258078165c	no	28
<b>Warnings:</b>					
<b>Information:</b>					
25	Non Patent Literature	P50-COPPER ET CHRISTOPHE ET AL SIMPLIFIED EFFICIENT METHOD FOR THE PREPARATION OF PDF	246666 353ca5e15b2e4d201526da7d4339399db46b899	no	4
<b>Warnings:</b>					
<b>Information:</b>					
26	Non Patent Literature	P53a-Crumplin Inhibition of Raf Kinase Activity.pdf	129960 7afac875758c734aa3383c3be17b847961548b	no	2
<b>Warnings:</b>					
<b>Information:</b>					
27	Non Patent Literature	P57-Daum The In and Out of Raf Kinases.pdf	923597 b6b65dc7c5aa818bac3d481bc22591ec15b73e90	no	7
<b>Warnings:</b>					
<b>Information:</b>					
28	Non Patent Literature	P66-Dumas Protein Kinase Inhibitors from the Urea Class.pdf	750454 28322b0f9b242edca77831614161c046b884691b601	no	10
<b>Warnings:</b>					
<b>Information:</b>					

29	Non Patent Literature	P67Dumas2000.pdf	155092	no	4
			65501a916c3401778ad0b0c0f624554c097a0e		
Warnings:					
Information:					
30	Non Patent Literature	P68-Dumas1-Phenyl-5-pyrazolylUreasPotentandSelectivep38KinaseInhibitors.pdf	281356	no	4
			b405c5dc9d86ca3a99f4efed88c2d8c3007626d7		
Warnings:					
Information:					
31	Non Patent Literature	P68a-DumasJGrowthFactorReceptorKinase.pdf	1180537	no	12
			5ab3c8d78c33817c71d451912d9802ed61db3bb		
Warnings:					
Information:					
32	Non Patent Literature	P68b-DumasJProteinKinaseInhibitors.pdf	1745212	no	25
			3106e05d2801d11d80b37eab03eada17b54774		
Warnings:					
Information:					
33	Non Patent Literature	P166-LyonsDiscoveryofaNovelRafKinaseInhibitor.pdf	816218	no	8
			8eac88eb1c240da1dce3c172182060977a069d31		
Warnings:					
Information:					
34	Non Patent Literature	P68c-DumasetalOral.pdf	83425	no	1
			99d573c44638c0dad8b0318c29036134b51aacc		
Warnings:					
Information:					
35	Non Patent Literature	P69-DumasRecentDevelopmentsinDiscoveryofProteinKinaseInhibitorsfromtheUreaClass.pdf	1279668	no	17
			db37827f62be332c6bf16619186835d3ab7a13		
Warnings:					
Information:					
36	Non Patent Literature	P70-DUMASETAL-SynthesisOrallyActivep38.pdf	367020	no	4
			e90c2ced8ba97ac4d1270bed121c7356ae2009		
Warnings:					
Information:					
37	Non Patent Literature	P107-GURA0009C02-SystemsIdentifyingNewDrugs.pdf	475596	no	5
			e3c278cc2398d29633615d1161e4c4d694052		
Warnings:					
Information:					

38	Non Patent Literature	P147-KubotaSynthesisandStructureactivity.pdf	168474 3a1ce5677b01ea81131bfad478bc5c7411c53d	no	1
<b>Warnings:</b>					
<b>Information:</b>					
39	Non Patent Literature	P149-KUMAR-ET-AL-DrugsTargetedProteinKinases-1.pdf	1326625 d7973ePebc19ba0135d2059c939a6a7941bb4	no	14
<b>Warnings:</b>					
<b>Information:</b>					
40	Non Patent Literature	P224-ReganPyrazoleUrea-BasedInhibitorsofp38MAPKinaseFormLeadCompoundtoClinicalCandidate.pdf	1709151 ba0f3c673808c17186c7213d3f914b72b13853	no	15
<b>Warnings:</b>					
<b>Information:</b>					
41	Non Patent Literature	P248-SmithDiscoveryofHeterocyclicUreasasNewClassofRafKinaseInhibitors.pdf	355827 07d6281ed65d11deeb0ead928f166cfc3805	no	4
<b>Warnings:</b>					
<b>Information:</b>					
42	Non Patent Literature	P249-SMITHETAL-RecentAdvancesRAF.pdf	38048 8ba0b20242fc280afe3ba9c3b2cd1416c59b602	no	1
<b>Warnings:</b>					
<b>Information:</b>					
43	Non Patent Literature	P276-Thaimattam3D-QSA.pdf	962868 04b4ae9aedc280338db61ec5ae91cf1eccd41690	no	11
<b>Warnings:</b>					
<b>Information:</b>					
44	Non Patent Literature	P278-ThompsonRecentProgressinTargetingtheRaf-MEK-ERKPathwaywithInhibitorsinCancerDrugDiscovery.pdf	656952 fbc3496ad7aeb94a6a88b16ce07bae543cc13cd	no	8
<b>Warnings:</b>					
<b>Information:</b>					
45	Non Patent Literature	P294-WilsonTheStructuralBasisfortheSpecificityofPyridinylimidazole.pdf	723222 aed136d6ababafce9a5cd946c1ea00482523cd	no	9
<b>Warnings:</b>					
<b>Information:</b>					
46	Non Patent Literature	P312-XP001152608KubotaSynthesisandStructureActivity.pdf	60045 db3a96f7222b02f8c0e8980bd24a1b1758605	no	1
<b>Warnings:</b>					
<b>Information:</b>					

47	Non Patent Literature	P313-RiedletalPotentRafKinaseInhibitorsfromtheDiphenyl.pdf	43951 5482a0d7acd18d73951c23d892ce0b534f5d2	no	1
<b>Warnings:</b>					
<b>Information:</b>					
48	Non Patent Literature	P315-AbstractofDE3305866A.pdf	54521 eKwrcd049d807bcb7928e4fc999595130e17	no	1
<b>Warnings:</b>					
<b>Information:</b>					
49	Non Patent Literature	P316-AbstractofEP4931A.pdf	56012 a15a07131ed946615f8bc21a5c0e8513a0d59a021	no	1
<b>Warnings:</b>					
<b>Information:</b>					
50	Non Patent Literature	P317-AbstractofEP16371.pdf	70897 98c116658c1375e1b0f91cd5c0fd1601b07878a	no	1
<b>Warnings:</b>					
<b>Information:</b>					
51	Non Patent Literature	P318-AbstractofEP16371A.pdf	52264 58920e9a754152838f4790c0cd147231e76017	no	1
<b>Warnings:</b>					
<b>Information:</b>					
52	Non Patent Literature	P319-AbstractofEP0116932.pdf	98741 28b702aba1e0fbcab3b0d18bcb43151e307a77c3	no	2
<b>Warnings:</b>					
<b>Information:</b>					
53	Non Patent Literature	P320-AbstractofEP0116932A1.pdf	98161 7a4c08a0d570003102b01e1c5ef5320eb3bb7c	no	2
<b>Warnings:</b>					
<b>Information:</b>					
54	Non Patent Literature	P321-AbstractofEP0202538A1.pdf	175567 63d13a8c528c521c590846f930609a024528c0	no	3
<b>Warnings:</b>					
<b>Information:</b>					
55	Non Patent Literature	P322-AbstractofEP0202538A1.pdf	219857 918c9060b0c761318a0b7318c385750d29b7e0d	no	4
<b>Warnings:</b>					
<b>Information:</b>					

56	Non Patent Literature	P323-AbstractofEP0405233A1.pdf	62671 2ef8f8f3ac98e6d2881ef0c0afcd2f8f02f1ee3	no	2
<b>Warnings:</b>					
<b>Information:</b>					
57	Non Patent Literature	P324-AbstractofEP0405233A1.pdf	46936 ff5c74416c9b6b43e8527e64f8bb126095c2855	no	1
<b>Warnings:</b>					
<b>Information:</b>					
58	Non Patent Literature	P325-AbstractofEP676395A.pdf	189634 66d8f8bbcf99c5117e7ff1cafd2f8cd528c9d98	no	3
<b>Warnings:</b>					
<b>Information:</b>					
59	Non Patent Literature	P68d-Dumas/RafKinaseInhibitors.pdf	230963 db3b999f8ef0c7cfc7dc40071de96d60c6aee6	no	2
<b>Warnings:</b>					
<b>Information:</b>					
60	Non Patent Literature	P326-AbstractofEP0676395A2.pdf	46706 b3d579ac580e57b1f1f1ac4d260569243d1c1994e	no	1
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			53712874		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

#### New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

#### National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

#### New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.